R Diagnostics SARS Coronavirus Detection Karen K. Y. Young, Ph.D. Roche Molecular Diagnostics Thomas Emrich, Ph.D. Roche Applied Sciences.

Slides:



Advertisements
Similar presentations
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
Advertisements

Mutation testing in the EGFR gene
Real Time under an IDE – CDCs PCR and ELISA Investigational Protocols.
HIV Counselling and Testing
Office of Infectious Diseases Computational Challenges for Infectious Diseases Michael Shaw, PhD OID/Office of the Director.
Affordable Resistance Testing for Africa (ART-A)
Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.
The Role of Mobile Medical Platforms in Pandemic Control & Treatment & Safe, Effective, Temperature Stable Diagnostic System ADAS Group.
The Current Pipeline for Point-of-Care Virologic Testing for HIV/AIDS Scaling up Virologic Diagnostic HIV Testing in Infants and Rationalizing Decentralization.
SPECIMEN HANDLING: from patient bedside to the laboratories (clinical, commercial and public health) Patricia A. Somsel, Dr.P.H. Michigan Department of.
Technical and Operational Considerations for Scaling Up
REAL TIME PCR ………A step forward in medicine
Improved Reflexive Testing Algorithm for Hepatitis C Infection Using Signal-to-Cutoff Ratios of a Hepatitis C Virus Antibody Assay K.K.Y. Lai, M. Jin,
1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.
MLAB 2434 – CLINICAL MICROBIOLOGY SUMMER, 2005 CECILE SANDERS & KERI BROPHY Chapter 7 – General Concepts in Specimen Collection and Handling.
Challenges of the 2009 H1N1 Pandemic Influenza: Charles Penn Global Influenza Programme World Health Organization Geneva.
Principles of Outbreak Management
SARS Timeline Nov 16 ‘02 Feb 11 ‘03 Feb 28 March 11 March 12 March 19 March 27 April 5 April 9 April 14 April 17 April 28 First cases Hong Kong WHO Sequence.
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
Plant virus infections induce tremendous economic losses for agricultural production each year in the U.S. Accurate and reliable diagnosis of the pathogens.
DR MOHAMMED ARIF. ASSOCIATE PROFESSOR. CONSULTANT VIROLOGIST. HEAD OF THE VIROLOGY UNIT. Viral infection of the respiratory tract -- 2.
Chlamydia trachomatis testing Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, MASA What is Chlamydia trachomatis? Chlamydia.
Diagnostic Assays to Plan Specific Drug Treatment Elizabeth Hammond MD.
Einstein-Montefiore CFAR Virology Core Director: Dr. Ganjam V. Kalpana, Ph.D.
Generic Automated Sample Preparation for Commercial NAT Assays
Laboratory Training for Field Epidemiologists Viral cultures Investigation strategies and methods May 2007.
Ensuring the Quality of Genetic Testing ICORD Meeting September 14, 2007 Lisa Kalman, PhD Coordinator, GeT-RM CDC
Ilesh V. Jani, MD PhD Instituto Nacional de Saúde Maputo, Mozambique.
1 WHO Communicable Diseases, Surveillance & Response SARS Diagnostics and Laboratory Needs: the WHO Perspective C.E. Roth Dangerous and New Pathogens Global.
Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.
SEARO –CSR Early Warning and Surveillance System Module Case Definitions.
Sheila Negrini Parmezan São Paulo, Introduction The neuraminidase inhibitors (NAIs), oseltamivir and zanamivir, are currently the antiviral drugs.
Julia Robbins August 11, Objectives Clinical Significance of MRSA in Healthcare Setting Principle of assay Assay Procedure Assay Perfomance.
WHO EQAP for the detection of influenza A virus subtype by PCR Wilina Lim Centre for Health Protection Hong Kong SAR, China.
U N I V E R S I T Y O F M I C H I G A N S C H O O L O F D E N T I S T R Y 1 Quality Assessment and Assurance of Clinical Care Programs.
WHO EQAP for the detection of influenza A virus subtype by PCR Centre for Health Protection Hong Kong SAR, China.
SARS. What is SARS? Severe Acute Respiratory Syndrome Respiratory illness Asia, North America, and Europe Previously unrecognized coronavirus.
Ilesh V. Jani, MD PhD Instituto Nacional de Saúde Maputo, Mozambique.
Clinical Approach to the Diagnosis of SARS Joshua P. Metlay, MD, PhD VA Medical Center Division of General Internal Medicine Center for Clinical Epidemiology.
Communicable Disease Surveillance and Response, WHO Avian Influenza Credit: WHO Viet Nam.
History of ILC Involvement in NAT Standardization 1998: Inter-Organization Discussion for the Establishment of Standard Reference Material for Nucleic.
W W W. Q I A G E N. C O M Dirk Heckel, PhD Diagnostic Sample Preparation and Stabilization QIAGEN GmbH.
Laboratory Results and Operations in WHO Phase 6 Dr. Attaporn Taweetungtragoon CYBELES Phnom Penh, Cambodia October 12-15, 2009.
Experience with SARS Laboratory Diagnostics JSM Peiris, LLM Poon, Y Guan, KH Chan. The University of Hong Kong & Queen Mary Hospital.
The Application of Real-Time PCR in the Diagnosis of Infectious Disease The Application of Real-Time PCR in the Diagnosis of Infectious Disease T.P.Sloots.
Using Real-Time PCR to Determine Blood Type. Lightcycler data.
Presentation on Longhorn Vaccine & Diagnostics LLC PrimeStore® Suite of Products and Pipeline 1747 Citadel Plaza, Suite 206, San Antonio, Texas
National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011 R. Suzanne Beard, Ph.D. Abstract/poster: TUPDC0103.
Rapid Molecular Diagnostic Test of HIV-1 Purified RNA from Plasma Michael M. Ling, Ph.D
HEALTH FORUM GASTEIN Crisis management and health policy for SARS and influenza control EUROPEAN UNION COOPERATION ON SARS CONTROL George Gouvras Health.
Pandemic Influenza Workshop, Working Group #3 Influenza Diagnostics for Surveillance April 4, 2005.
DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern Experience with Roche´s COBAS AmpliPrep/COBAS TaqMan96 automated PCR system in two large.
Phar. Nhat Mang/ Roche Vietnam
Public Health Perspective on SARS Diagnostics Stephen M. Ostroff Deputy Director National Center for Infectious Diseases, CDC.
Progress on Study to Validate Synthetic Materials for Use as Calibrators and References SoGAT XIX Bern, 14 June 2006 Roberta M. Madej Roche Molecular Diagnostics.
RESULTS Division of Arboviruses, Center for Immunology and Pathology, National Institute of Health, Korea Centers for disease control, Osong, Korea BACKGROUND.
Severe Acute Respiratory Syndrome (SARS) AA Model for Preparedness for Emerging Diseases Finding and Filling Gaps.
SARS: International Coordination SARS: International Coordination and Collaboration James W. LeDuc, Ph.D. Director, Division of Viral and Rickettsial Diseases.
TIGER * Biosensor for Emerging Infectious Disease Surveillance *Triangulation Identification for Genetic Evaluation of Risks Ranga Sampath David Ecker.
Viro-chip Microarray Using a Pan-Viral Microarray Assay (Viro-chip) to Screen Clinical Samples for Viral Pathogens.
COMPARISON OF LABORATORY DIAGNOSTIC PROCEDURES FOR DETECTION OF MYCOPLASMA PNEUMONIAE IN COMMUNITY OUTBREAKS KATHLEEN A. THURMAN, NICHOLAS D. WALTER, STEPHANIE.
Quantification of Parvovirus B19 DNA Using COBAS AmpliPrep Automated Sample Preparation and LightCycler Real-Time PCR Stefan Schorling, Gunnar Schalasta,
CDC and support for Point of Care Testing Accreditation Muthoni Junghae CDC-Kenya LAUNCH OFF POINT OF CARE TESTING ACCREDITATION PROGRAM PANAFRIC HOTEL-18TH.
Investigation strategies and methods
Karen M. Williamson RN, MScN, PhD(c) Maher M. El-Masri RN, PhD
Bioinformatics for plant biosecurity and surveillance systems
Priya Sampathkumar, MD, Zelalem Temesgen, MD, Thomas F
Coronaviruses Co Vs..
Next Generation Sequencing Market. Report Description and Highlights According to Renub Research market research report “Next Generation Sequencing (NGS)
Presentation transcript:

r Diagnostics SARS Coronavirus Detection Karen K. Y. Young, Ph.D. Roche Molecular Diagnostics Thomas Emrich, Ph.D. Roche Applied Sciences

r Diagnostics Critical Issues Logistical challenges –Nature of epidemic not well understood Seasonal? Reservoir? –For rapid introduction of diagnostic assay Need to mobilize resources quickly Need partnership with regulatory agencies –Sample acquisition –IP landscape

r Diagnostics Critical Issues Technical challenges –Optimal sample type? Blood/serum/plasma Respiratory specimen Stool/urine –Sample preparation issues Removal of inhibitors Efficient lysis/preservation of RNA –Viral sequence heterogeneity Mutation Recombination –Standardization/reference material

r Diagnostics Roche’s Response Rapid development of research assay –Quantitative real-time PCR –LightCycler –Sample preparation defined by user Development of IVD assay if warranted –Regulatory guidance needed for performance requirements –Lessons learned from research assay –Automated sample preparation –TaqMan PCR –Full-process controls

r Diagnostics Research Assay Status LightCycler-based assay –Real-time PCR –Quantitative, external calibration standards –Internal control User-defined sample preparation In-house evaluation of positive samples completed World-wide trial at beta sites on-going

r Diagnostics Research Assay Performance In-house evaluation –Positive samples from Hong Kong (N=40) –Sample types Nasal-pharyngeal aspirates Stool Urine Throat swabs

r Diagnostics Research Assay Performance In-house evaluation

r Diagnostics Challenges to SARS diagnosis Many unknowns –Nature of epidemic? –Natural history of infection? –Most appropriate sample type? –Optimal sample handling?

r Diagnostics Challenges to SARS diagnosis To effect rapid introduction of diagnostic assay –Requires dedicated resources –Co-operation from regulatory/public health agencies needed Definition of performance requirements Standardization for assessment of assay performance Availability of reference standards Availability of clinical samples for assay development and evaluation